Old Web
English
Sign In
Acemap
>
authorDetail
>
Mark E. Cooper
Mark E. Cooper
Merck & Co.
Medicine
Population
Type 2 diabetes
Kidney disease
Internal medicine
3
Papers
150
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Original Investigation Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes
2015
American Journal of Kidney Diseases
Mark E. Cooper
Vlado Perkovic
Janet B. McGill
Per-Henrik Groop
Christoph Wanner
Julio Rosenstock
Uwe Hehnke
Hans-Juergen Woerle
Maximilian von Eynatten
Show All
Source
Cite
Save
Citations (0)
Original Investigation Hemoglobin Stability in Patients With Anemia, CKD, and Type 2 Diabetes: An Analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) Placebo Arm
2013
American Journal of Kidney Diseases
Hicham Skali
Julie Lin
Marc A. Pfeffer
Chao-Yin Chen
Mark E. Cooper
John. J. V. McMurray
Allen R. Nissenson
Giuseppe Remuzzi
Patrick S. Parfrey
Nairne Scott-Douglas
Ajay K. Singh
Show All
Source
Cite
Save
Citations (0)
Risk Scores for Predicting Outcomes in Patients with Type 2 Diabetes and Nephropathy: The RENAAL Study
2006
Clinical Journal of The American Society of Nephrology
William F. Keane
Zhongxin Zhang
Paulette A. Lyle
Mark E. Cooper
Dick de Zeeuw
Jean-Pierre Grünfeld
James P. Lash
Janet B. McGill
William E. Mitch
Giuseppe Remuzzi
Shahnaz Shahinfar
Steven M. Snapinn
Robert D. Toto
Barry M. Brenner
Show All
Source
Cite
Save
Citations (150)
1